APPYEA, INC

APPYEA, INC is a U.S.-listed development-stage company centered on its AppySleep wristband, a biofeedback product intended to monitor and treat snoring and sleep apnea. The company’s business is built around an exclusive worldwide license held by its Israeli subsidiary to commercialize sensor and software solutions for sleep-related monitoring and treatment. Its current activity is still early-stage and highly dependent on product development, regulatory progress, and external financing rather than recurring operating scale. Recent filings show only minimal product revenue, with management focused on completing IOS design and development, building distribution, and pursuing future regulatory approvals and reimbursement pathways.

17

0.07

0.07

— APPYEA, INC
%
Wearable sleep treatment device100% The AppySleep wristband is the company’s core product candidate for biofeedback-based snoring treatment.
Sleep monitoring software and sensors0% Licensed sensor and software solutions are intended to monitor snoring and sleep apnea severity.
Sleep apnea treatment IP0% Licensed intellectual property covers treatment solutions and speech-analysis-based severity estimation.
Commercialization and distribution0% The company is building channels through healthcare providers, insurers, and online webstores.

APPYEA’s target customers are healthcare institutions, including hospitals and medical providers, that may adopt the...

  • Healthcare providers and hospitalsprimary

    They would buy or recommend the wristband and related solutions if the product improves diagnosis and reduces treatment costs.

  • Direct-to-consumer buyerssecondary

    Individuals may purchase the AppySleep wristband online for snoring and sleep apnea-related use.

  • Insurance and reimbursement stakeholderssecondary

    Private insurers and payors matter because reimbursement could materially improve adoption and affordability.

The company is headquartered in the United States but its commercialization structure is international because the core...

  • •United States is the operating and logistics base for product distribution
  • •Israel is the source of the licensed intellectual property and subsidiary structure
  • •Worldwide commercialization rights support a broad addressable market
  • •Online webstore sales are intended to reach customers globally
  • •Cross-border IP and licensing create foreign exchange and execution exposure

APPYEA’s near-term strategy is to finish IOS design and development of the AppySleep wristband and use financing...

01
Complete product developmentshort-term

The company needs a finished, marketable wristband before it can scale sales or validate clinical value.

02
Build commercialization channelsshort-term

Distribution through providers and online channels is necessary to move from prototype-stage activity to sales.

03
Secure reimbursement and regulatory acceptancemedium-term

Insurance coverage and regulatory approvals would materially improve adoption and credibility.

The company faces substantial going-concern and financing risk because it has recurring losses, limited revenue, and...

critical

Going concern and liquidity shortfall

The company has recurring losses, limited cash, and management states additional capital is required to maintain operations.

Scope
Operations and debt repayment
Materiality
high
high

Convertible note repayment and refinancing risk

Outstanding convertible notes were extended only if the company repays principal, interest, and a premium by the new maturity date, subject to raising capital.

Scope
Balance sheet and near-term cash needs
Materiality
high
high

Regulatory approval risk

The product is a health-related device and the company says it must pursue FDA clearance and international approvals before broader commercialization.

Scope
Product launch timing
Materiality
high
high

Commercial adoption and reimbursement risk

Sales depend on hospitals, providers, and insurers accepting the economic and clinical case for the product.

Scope
Revenue growth
Materiality
high
medium

License economics and royalty burden

The company owes royalties on net sales and may owe an exit fee, which can reduce future margins and transaction proceeds.

Scope
Gross margin and strategic flexibility
Materiality
medium
Revenue recognition timing
Can materially change quarter-to-quarter revenue comparability
Convertible notes and derivative valuation
Can create large non-operating gains or losses
Going-concern and liability classification
Affects investor assessment of solvency and disclosure quality
Royalty and exit-fee obligations
Can reduce future margins and transaction proceeds

Apogee Therapeutics, Inc.

APGE · Biological Products, (No Diagnostic Substances)

RemSleep Holdings Inc.

RMSL · Services-Personal Services

Sleep Cycle

SLEEP.ST · Technology

AbCellera Biologics Inc.

ABCL · Pharmaceutical Preparations

Owlet, Inc.

OWLT · Measuring & Controlling Devices, NEC

AdaptHealth Corp.

AHCO · Services-Home Health Care Services

: 11/08/2026